Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03567707 · ClinicalTrials.gov registry record · Early Phase 1

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

A Early Phase 1 study of Asthma and Allergic Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Active
Registry status
Early Phase 1
Development phase
114
Enrollment target
2
Study locations

NCT03567707: Active Early Phase 1 study of Asthma and Allergic Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT03567707 is a Early Phase 1 study of Asthma and Allergic Diseases that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 114 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03567707, a Early Phase 1 study of Asthma and Allergic Diseases, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
114 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to assess at how differences in the microbiome (naturally occurring bacteria) of a baby may protect, or put a baby at risk, for allergic problems. The microbiome refers to the thousands of bacteria and molds that live in and on our bodies. The microbiome plays an important role in our health. Differences in the microbiome can affect our immune system in ways that might make some people more likely to get allergies and asthma. Early life events and exposures are very important for establishing the human microbiome. The newborn baby's microbiome changes very quickly during the first weeks and months of life. There is information that suggests C-section birth is associated with higher risk of certain diseases, including allergies and asthma. Some researchers think one reason for this is that passing through the mother's vaginal canal during birth exposes the baby to bacteria that promote healthy immune system development, something that C-section babies don't get. Transferring these potentially beneficial vaginal bacteria to C-section babies may help prevent some diseases later.

Primary Outcome

Evaluation for the presence of food allergens (egg, milk, and peanut) in infants at 12 months of age. Sensitization is defined by a serum IgE ≥ 0.1 kUA/mL for each allergen.

Conditions Studied

Interventions

  • OTHER Standard care
  • DRUG Vaginal seeding
  • DRUG Placebo Seeding
  • OTHER Post-seeding Care

Study Locations (2)

New York

  • Mount Sinai West - New York
  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2018-11-28
Est. Completion 2027-01
Phase Early Phase 1

What the registry record for NCT03567707 still lists

NCT03567707 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Standard care is the first listed.

NCT03567707 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03567707 about?

NCT03567707 is a clinical study titled "Vaginal Microbiome Exposure and Immune Responses in C-section Infants". The purpose of this research study is to assess at how differences in the microbiome (naturally occurring bacteria) of a baby may protect, or put a baby at risk, for allergic problems. The microbiome refers to the thousands of bacteria and molds that live in and on our bodies. The microbiome plays a...

What is the current status of trial NCT03567707?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 114 participants. The study started on 2018-11-28. Estimated completion is 2027-01.

What conditions does trial NCT03567707 study?

This clinical trial studies the following conditions: Asthma, Allergic Diseases.

What interventions are being tested in trial NCT03567707?

The interventions under investigation include: Standard care (OTHER), Vaginal seeding (DRUG), Placebo Seeding (DRUG), Post-seeding Care (OTHER).

Who is sponsoring clinical trial NCT03567707?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03567707 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03567707's enrollment target sits among peer trials

114 206th of 374 higher than 169 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03567707, the US trial registry maintained by the National Library of Medicine. NCT03567707 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.